NCT03796884View on ClinicalTrials.gov

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Colorectal AdenomaStage 0 Colorectal Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8
Interventions
DRUG

Linaclotide

Given PO

OTHER

Placebo

Given PO

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

19126

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

98108

VA Puget Sound Health Care Sysem, Seattle

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03796884 - Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | Biotech Hunter | Biotech Hunter